SciSparc Ltd. (SPRC) 주식 분석

회사 개요

SciSparc Ltd. operates as a clinical-stage pharmaceutical company dedicated to developing drugs that leverage cannabinoid therapies for various therapeutic indications. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which is characterized by high research and development costs and regulatory scrutiny regarding novel drug mechanisms. SciSParc currently maintains a very small operational scale, employing only 2 individuals while holding a market capitalization of $1.93 million and reporting trailing twelve-month revenue of $1.31 million. These valuation and revenue figures indicate that the company is a micro-cap entity with minimal market penetration relative to established peers, reflecting its early-stage status in the biotechnology development pipeline where significant capital deployment is required to advance clinical programs such as SCI-110 for Tourette syndrome and SCI-210 for autism spectrum disorder.

재무 건전성

The company's financial statements reveal a revenue stream of $1.31 million for the trailing twelve months, accompanied by a net income loss of $6.48 million and an EBITDA of -$7.029 million. The substantial disparity between the positive revenue of $1.31 million and the significant net loss of $6.48 million indicates a highly leveraged cost structure typical of clinical-stage biotechnology firms, where research and development expenditures vastly exceed current sales generated. SciSparc reports no available free cash flow data, which suggests that the company's financial flexibility is currently constrained by heavy cash burn rates associated with advancing its drug development programs. Analysis of the three primary margins shows a gross margin of 38.7%, which is healthy for a biotech firm, yet this is overshadowed by an operating margin of -569.5% and a profit margin of 0.0%, both of which highlight the severe operational inefficiencies and heavy investment phases inherent to the company's current lifecycle. The balance sheet reflects a debt position of $0, while cash reserves are not listed in the available data, resulting in a debt-to-equity ratio that is unavailable for calculation. Although the current ratio is not disclosed, the operating margin of -569.5% implies that operating expenses are roughly five times the revenue level, creating significant pressure on short-term liquidity before any external funding is secured. Furthermore, the return on equity stands at -1281.5% and the return on assets is unavailable, metrics that collectively reveal that management is currently unable to generate positive returns on the capital invested or the shareholders' equity due to the company's ongoing losses and lack of profitability.

밸류에이션 평가

SciSparc's valuation metrics present a mixed picture typical of unprofitable biotechnology assets, with a trailing P/E ratio of 0.00 and a forward P/E that is not available. The absence of a forward P/E and the zero trailing P/E imply that the market is not currently pricing in near-term earnings growth, as the company has not yet achieved profitability to support a standard earnings-based valuation. The price-to-book ratio is recorded at 0.02, indicating that the market values the company at a fraction of its book value, which suggests a deep discount relative to the assets recorded on the balance sheet rather than a premium for future growth potential. Alternative valuation metrics such as the price-to-sales ratio of 1.48 and an EV/EBITDA that is not available provide context for investors analyzing the company based on revenue multiple rather than earnings power. The stock's price volatility is significant, with a 52-week high of $94.50 and a 52-week low of $3.32, placing the current trading range within a highly volatile band that reflects the speculative nature of the asset. With a beta of 1.33, SciSparc exhibits price volatility that is 33% higher than the broader market, meaning the stock is expected to amplify market movements and pose higher risk for investors seeking stability.

Growth & Income

Revenue growth and earnings growth for the year-over-year period are both unavailable, which precludes a direct comparison of the speed at which earnings are growing relative to revenue expansion. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that SciSparc reinvests its limited capital into research and development rather than returning value to shareholders through cash distributions. Given the negative net income and lack of cash flow, the company cannot sustain a dividend payout, and the 0.0% payout ratio accurately reflects its policy of retaining earnings to fund its clinical-stage operations. The overall growth and income profile of SciSparc is characterized by a complete lack of historical growth data and zero income distribution, positioning the investment strictly as a high-risk venture play dependent on future clinical trial successes rather than current financial performance or shareholder returns.